This study uses genome-wide genotype and lymphoblastoid cell line (LCL) transcriptomic data derived from 412 of 944 Cholesterol and Pharmacogenetics (CAP) 40 mg/day 6 week simvastatin clinical trial participants (ClinicalTrials.gov ID: NCT00451828) [9 (link)]. Demographic and phenotypic characteristics of this participant subset are shown in Table 5 . Self-reported white CAP participants were genotyped as previously described on one or more (Illumina HumanHap300, Human610-Quad, custom iSelect and Cardio-Metabochip) platforms [50 (link), 51 (link)], and self-reported black participants were genotyped on the Illumina HumanOmni2.5Exome and, for the majority of participants, the Cardio-Metabochip and Immunochip.
Characteristics of European ancestry and African American ancestry CAP participants used in eQTL analyses
| African Americans | European Americans | |
|---|---|---|
| N | 153 | 259 |
| Gender | 53.6% Female | 47.9% Female |
| Age (years) | 53.7 ± 12.8 | 54.2 ± 12.0 |
| BMI | 30.1 ± 6.0 | 27.9 ± 5.7 |
| Smoker | 28.8% | 10.8% |
| aTotal Cholesterol (mg/dl) | 204 ± 36 | 214 ± 37 |
| aLDL Cholesterol (mg/dl) | 129 ± 35 | 135 ± 33 |
| aHDL Cholesterol (mg/dl) | 55 ± 17 | 54 ± 17 |
| aTriglycerides (mg/dl) | 103 ± 49 | 125 ± 67 |
| % change TC | -26 ± 10% | −28 ± 9% |
| % change LDLC | −40 ± 13% | −43 ± 11% |
| % change HDLC | 2 ± 11% | 5 ± 11% |
| % change TG | −14 ± 26% | −17 ± 24% |
Values are mean ± SD. aValues are prior to the start of statin treatment
Free full text: Click here
